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Introduction: Ischemic stroke is a leading cause of death and disability, but treatment options are severely limited.
Cell therapy offers an attractive strategy for regenerating lost tissues and enhancing the endogenous healing
process. In this study, we investigated the use of human embryonic stem cell-derived neural precursors as a cell
therapy in a murine stroke model.
Methods: Neural precursors were derived from human embryonic stem cells by using a fully adherent SMAD
inhibition protocol employing small molecules. The efficiency of neural induction and the ability of these cells to
further differentiate into neurons were assessed by using immunocytochemistry. Whole-cell patch-clamp recording
was used to demonstrate the electrophysiological activity of human embryonic stem cell-derived neurons. Neural
precursors were transplanted into the core and penumbra regions of a focal ischemic stroke in the barrel cortex of
mice. Animals received injections of bromodeoxyuridine to track regeneration. Neural differentiation of the
transplanted cells and regenerative markers were measured by using immunohistochemistry. The adhesive removal
test was used to determine functional improvement after stroke and intervention.
Results: After 11 days of neural induction by using the small-molecule protocol, over 95% of human embryonic
stem-derived cells expressed at least one neural marker. Further in vitro differentiation yielded cells that stained for
mature neuronal markers and exhibited high-amplitude, repetitive action potentials in response to depolarization.
Neuronal differentiation also occurred after transplantation into the ischemic cortex. A greater level of
bromodeoxyuridine co-localization with neurons was observed in the penumbra region of animals receiving cell
transplantation. Transplantation also improved sensory recovery in transplant animals over that in control animals.
Conclusions: Human embryonic stem cell-derived neural precursors derived by using a highly efficient small-
molecule SMAD inhibition protocol can differentiate into electrophysiologically functional neurons in vitro. These
cells also differentiate into neurons in vivo, enhance regenerative activities, and improve sensory recovery after
ischemic stroke.
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Each year, approximately 795,000 people in the United
States experience a stroke and it is now the fourth leading
cause of death when considered separately from other car-
diovascular diseases. It is also a leading cause of disability,
and 26% of stroke survivors over 65 are still dependent on
others for daily activities at 6 months after stroke [1].
However, administration of tissue plasminogen activator
in the acute phase of stroke is still the only US Food and
Drug Administration-approved treatment for this preva-
lent cause of death and morbidity and its application is
limited by a narrow therapeutic window and a number of
complications [2]. Other drugs that mediate significant
neuroprotection in animal models and small trials, such as
erythropoietin, have failed to demonstrate efficacy in
large-scale human clinical trials [3].
Studies on treatment in the chronic phase of stroke
are generally focused on recovering function through tis-
sue repair and regeneration. Cell therapy is an attractive
strategy for these goals, as transplanted cells may replace
dead or damaged cells in addition to providing trophic
support to supplement endogenous healing [4-6]. Vari-
ous types of neural precursors, such as a conditionally
immortalized cell line derived from human fetal tissue
(now in clinical trials) [7-10], lines derived from carcin-
omas [11,12], fetal neuronal stem cells [13,14], mouse
neural precursors derived from the post-stroke cortex
[15], region-specific murine embryonic precursors [16],
and precursors derived from mouse [17-19] or human
[20-26] embryonic stem cells have been used in experi-
mental models.
Human embryonic stem (hES) cells are pluripotent and
can proliferate indefinitely in culture, both useful proper-
ties in the context of cell therapy. However, although
neural differentiation is often seen as the default pathway
for these cells [27], directed differentiation is difficult to
optimize. Common neural differentiation protocols often
use suspension culture techniques [28-33] or co-culture
with feeder cells [31,34,35], both of which can introduce
heterogeneous microenvironmental cues. Feeder cells,
which are generally of rodent origin, also introduce xeno-
genic contaminants that can increase the immunogenicity
of transplanted cells. Additionally, expensive recombinant
factors like noggin are often used to obtain neural precur-
sors [29,36-38], and the expense associated with these fac-
tors can be a limiting factor in scaling up cultures to the
level required for preclinical development. More recently,
there has been a greater focus on the use of fully adherent
protocols [37] and small molecules [39] to cut down on
heterogeneity and cost.
We previously reported the use of a fully adherent differ-
entiation protocol that relies primarily on small molecules
for differentiation, reducing the cost and heterogeneity in
in vitro differentiation of neural precursors and neurons[40]. In the present study, we further characterize the
in vitro differentiation of cells by using this protocol and
demonstrate the use of hES cell-derived neural precursors
in a murine model of ischemic stroke. We demonstrate
that neural precursors derived by this method provide a
useful cell population for cell-based stroke therapy.
Methods
Human embryonic stem cell maintenance and
differentiation
H1 hES cells (p35-50; WiCell, Madison, WI, USA) were
maintained on hES cell-qualified Matrigel (BD Biosciences,
Sparks, MD, USA)-coated dishes in mTeSR1 medium
(Stem Cell Technologies, Vancouver, BC, Canada). Differ-
entiation was carried out as previously described [40].
Briefly, neural precursors were obtained by using a modi-
fied version of the differentiation protocol developed by
Chambers and colleagues [37]. The neural precursors were
seeded as single cells on growth factor reduced Matrigel
(BD Biosciences)-coated dishes and grown to adherence,
and SMAD inhibition was applied by using dorsomorphin
(Tocris, Ellisville, MO, USA) and SB431542 (Stemgent,
Cambridge, MA, USA). For in vitro differentiation of neu-
rons, neural precursors were re-seeded as single cells and
grown in a mixture of N2 and B27 medium (Invitrogen
Corporation, Carlsbad, CA, USA) supplemented with 10
ng/mL basic fibroblast growth factor (bFGF) (R&D Sys-
tems, Minneapolis, MN, USA).
Differentiation was partially confirmed by staining by
using standard protocols [41]. Cells were fixed in 4%
paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA),
permeabilized by using Triton-X-100 (G-Biosciences, St.
Louis, MO, USA), blocked by using 1% fish gelatin
(Sigma-Aldrich), and primary antibodies (nestin, neur-
onal nuclei (NeuN), neurofilament L (NF); Millipore,
Billerica, MA, USA; paired box gene 6 (PAX6): Covance,
Princeton, NJ, USA; sex-determining region Y-box 1
(SOX1): Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were applied overnight at 4°C in phosphate-
buffered saline. Cy3- or Alexafluor 488-conjugated
antibodies were applied for 1 to 2 hours at room
temperature, and Hoechst 33324 (Invitrogen Corpor-
ation) or 4′,6-diamidino-2-phenylindole (DAPI) (Vector
Labs, Burlingame, CA, USA) was used to counterstain
nuclei. Cells expressing neural precursor markers were
quantified by using the ImageJ cell counter, and at least
7,000 cells were counted per sample and no fewer than
three samples were counted per marker.
Some antibodies were selected for Western blot ana-
lysis. Protein (30 μg) from each sample was loaded into
a gradient gel and run at constant current until protein
markers had adequately separated. They were transferred
onto polyvinyl difluoride membranes that were then
probed by using standard protocols. Primary antibodies
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Thermo Fisher Scientific, Waltham, MA, USA; GluA2,
GluN3A, nestin, Millipore; GluN1, Cell Signaling, Danvers,
MA, USA; Nav1.1, Abcam, Cambridge, MA, USA) were
applied overnight at 4°C. Alkaline phosphatase (AP)- or
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies were applied for 1 to 2 hours at room temperature.
AP-conjugated antibodies were developed by using nitro-
blue tetrazolium and 5-bromo-4-chloro-3'-indolyphosphate
(NBT/BCIP) solution, and HRP-conjugated antibodies were
developed by using a Pierce ECL Detection Kit (Thermo
Fisher Scientific). Actin was used as a loading control.
Electrophysiological recording of differentiating cells
Whole-cell patch clamp recording was performed on cul-
tured cells exhibiting neuronal morphology at 7, 14, 21,
and 28 days after re-seeding. The measurements were
performed as in our previous studies by using an EPC9
amplifier (HEKA Elektronik, Lambrecht, Germany) at
room temperature [42]. The external solution (pH = 7.4)
contained 135 mM NaCl, 5 mM KCl, 2 mMMgCl2, 1 mM
CaCl2, 10 mM HEPES, and 10 mM glucose. The internal
solution (pH = 7.2) contained 120 mM KCl, 2 mM MgCl2,
1 mM CaCl2, 2 mM Na2ATP, 10 mM EGTA, and 10 mM
HEPES. Recording electrodes were pulled from borosili-
cate glass pipettes (Sutter Instrument, Novato, CA, USA)
and had a tip resistance of between 5 and 7 MΩ when
filled with the internal solution. Series resistance was com-
pensated by 75% to 85%. Linear leak and residual capaci-
tance currents were subtracted online by using a P/6
protocol. Action potentials were triggered by depo-
larization pulses and recorded under current-clamp mode
by using PULSE software (HEKA Elektronik), and data
were filtered at 3 KHz and digitized at a sampling rate of
20 KHz.
Delayed rectifier potassium current densities (IK) were
recorded from −60 to +60 mV with a 20 mV increment
and a holding potential of −70 mV in the presence of 0.5
μM tetrodotoxin to block sodium currents. The reported
current densities were measured at +40 mV. Transient
outward potassium current densities (IA) were elicited
from −60 to +40 mV with a 20-mV increment after a hy-
perpolarization of −110 mV for 500 ms. Peak amplitudes
were measured at +40 mV. Both current measurements
were normalized to cell size by using the capacitance of
the cell.
Ischemic stroke and cell transplantation
All procedures were approved by the Institutional Animal
Care and Use Committee and met National Institutes of
Health guidelines. Male 8- to 12-week-old C57/Bl6 mice
were subjected to a focal ischemic stroke as previously de-
scribed [41,43-45]. Briefly, during anesthesia with 2%
chloral hydrate, a 2.0- to 2.5-mm-diameter craniectomywas performed through the right parietal skull, and the
transparent dura was left intact over the whisker barrel
cortex. Four to five distal branches of the middle cerebral
artery serving the barrel cortex were ligated by using a
10-O suture through the dura. The creation of the whisker
barrel ischemic region was completed by bilateral occlu-
sion of the common carotid arteries (CCAs) for 7 minutes
followed by reperfusion. Blood flow reduction was con-
firmed (Figure 1) by using the PeriScan PIM II Laser Dop-
pler perfusion imager (Perimed AB, Cleveland, OH, USA)
during the 7-minute ligation of the CCAs. This stroke
model is focused on the whisker barrel cortex but also af-
fects the forelimb region of the sensorimotor cortex.
Cell transplantation was carried out 7 days after stroke.
Cells were labeled with a 1-hour exposure to 10 μg/mL
Hoechst 33324 and treated with accutase to obtain a
single-cell suspension. Cells were filtered through a 20-μm
mesh and resuspended in N2 medium. Animals were re-
anesthetized with 2% chloral hydrate. The ischemic infarc-
tion is well developed at this time, and the ischemic core
(white or pale region) and peri-infarct area can be directly
identified under an operating microscope through the cra-
nial window. Injection of 4 μL of cell suspension (trans-
plant group, 200,000 cells total) or medium (control
group) into the core and penumbra regions of the stroke
area was performed by using a Hamilton 80330 701 10-μL
removable-needle syringe (Hamilton Company, Reno, NV,
USA). Four injection sites (two in the core and two in the
penumbra, 1 μL each) were used and each was carried out
slowly (total injection time of 10 minutes). The needle was
kept in the injection site for 2 minutes before withdrawal
to prevent backflow of the injected solution. On the day of
the transplant, animals began receiving daily intraperito-
neal injections of 50 mg/kg bromodeoxyuridine (BrdU)
(Sigma-Aldrich) to label proliferating cells. These injec-
tions were continued until sacrifice. Animals received no
immunosuppression. Two to three days after injection,
one transplant animal per group (n = 4) was sacrificed to
assess graft survival. Staining was carried out on 10- to
20-μm sections by using the vendor instructions
(DeadEnd™ Fluorometric TUNEL System; Promega Cor-
poration, Madison, WI, USA).
Immunohistochemistry
Animals were sacrificed 28 days after transplantation
and brains were fresh-frozen in optimal cutting tem-
perature compound (OCT) (Sakura Finetek, Torrance,
CA, USA). Each 10-μm section on a slide was at least
100 μm from the previous section to avoid double-
counting of cells, and slides were light-protected to pre-
serve the Hoechst 33342 label. Slides were stained by
using standard protocols for NeuN (Millipore) to label
neurons, collagen IV (Col IV) (Millipore) to label vessels,
or BrdU (AbD Serotec, Oxford, UK) to label newborn
Figure 1 Cell differentiation and stroke model. (A) Timeline of the differentiation process, stroke induction, and testing. Neural precursors
were obtained approximately 2 weeks after seeding, and electrophysiology measurements were carried out every 7 days after re-plating.
Transplantation was carried out at the neural precursor stage, 1 week after stroke induction. Adhesive removal training took place in the week
before stroke. Testing was carried out 4 days after stroke and then 7, 14, 21, and 28 days after transplantation. BrdU injections were given daily
beginning on the day of transplantation. (B) Representative blood flow measurements before and during the 7-minute ligation of the CCA,
demonstrating a nearly complete blood flow reduction to the affected area.
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croscopy along the length of the penumbra region de-
fined morphologically as the region just outside the
stroke core. Z-stack imaging was used to confirm co-
localization. At least three sections per sample were
quantified for each measurement. Where possible, hu-
man cells were identified by the Hoechst tag applied
before transplantation.
Hoechst-positive cell counting in brain sections
Cell count of Hoechst-positive cells remaining in the
graft at 28 days was performed by following a modifica-
tion of the principles of design-based stereology. System-
atic random sampling was employed to ensure accurate
and non-redundant cell counting. Every section under
analysis was at least 100 μm away from the next. For
each animal, six 10-μm-thick sections spanning the en-
tire region of interest that crossed 600 μm around the is-
chemic core/peri-infarct region were counted. The total
number of Hoechst-positive cells on the six sections of
each slide was quantified.
Behavioral testing
Starting several days before stroke, animals were trained
in the adhesive removal task [46] until they could con-
sistently completely remove the adhesive dot from both
forepaws within 12 seconds. Both the time to contact
and time to remove the dot after contact were recorded.
Performance in this task was then measured 4 days after
stroke to obtain a baseline measurement for impairment.
Animals showing no impairment on the affected side
were rare and were removed from further behavioralstudy. Testing was repeated 7, 14, 21, and 28 days after
transplantation by an investigator blinded to the treat-
ment groups.
Statistical analysis
In vitro staining data are reported as the mean percent-
age ± standard deviation of cells positive for a marker.
Peak voltage and current density values are reported as
mean ± standard error of the mean (SEM) and were
compared by using analysis of variance with a Tukey
post hoc test. Peak voltage measurements of action po-
tentials are pooled from cultures at 5% and 20% O2 ten-
sion. For in vivo immunohistochemical data, the values
of mean ± SEM were compared by using a Student
t test. Normal distribution was confirmed by using the
Kolmogorov-Smirnov test.
A compound symmetry variance-covariance form in
repeated measurements was assumed for each behavioral
outcome. A signed rank test was used to determine the
significance of post-stroke impairment. Post-stroke base-
line measurements were compared between the control
and transplant groups by using the Mann–Whitney U
test. A repeated measures analysis using linear mixed
models via SAS Proc Mixed (version 9.2; SAS Institute
Inc., Cary, NC, USA) was performed for the longitudinal
measurements of the time to contact and time to re-
move obtained at 7, 14, 21, and 28 days. The fixed ef-
fects in the models include the subject’s treatment
group, time point, and interactions between treatment
group and time point. The models also include the post-
stroke baseline outcome measure (taken at 4 days) and
the outcome measure of the unaffected forepaw at the
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ferent post-stroke performance levels across subjects and
learning effects across time. The mixed linear models also
include the subject-specific random intercept to account
for between-subject random variability in outcome mea-
sures. All statistical tests were two-sided.
Results
Immunocytochemistry reveals highly efficient
differentiation of neural precursors
Neural differentiation of H1 hES cells was carried out by
using a fully adherent SMAD inhibition protocol employing
small molecules [37,40]. After 11 days of SMAD inhibition,
cells had lost all detectable expression of pluripotency
markers and had begun expressing neural precursor
markers such as nestin, PAX6, and SOX1. Nestin is an
intermediate filament protein that is expressed in the
embryonic neuroepithelium and in neural precursors
throughout the central nervous system [47,48]. PAX6 is
an important transcription factor in cortical development
[49,50] and is necessary for the development of the
thalamocortical tract [51]. We previously reported the ex-
pressions of these markers after SMAD inhibition with
SB431542 and dorsomorphin as 96% ± 3% and 75% ± 7%,Figure 2 hES cell-derived precursors express neural markers and diffe
11 after the beginning of SMAD inhibition; 96% ± 3% of cells expressed ne
expressed SOX1 (n = 3). Scale bars are 30 μm. (B) After re-plating for termi
evident after 7 days (a) and persisted through 28 days (b). These cells form
NF was evident (c). Scale bars are 10 μm. (C) At 28 days, cells expressed th
GluA1 and GluN2B are shown co-localized with NeuN and NF, respectively.
are 10 μm.respectively [40]. In the present study, we examined the
expression of SOX1, another transcription factor indicated
in the specification of early neural cell fate [52]. This
marker was expressed in 64% ± 9% of cells after 11-day
differentiation (Figure 2A). Taken together, these markers
indicate efficient differentiation into neural precursors,
and most of the cells are biased toward a forebrain lineage.
Staining was also used to verify the ability of these neural
precursor cells to differentiate into neurons in vitro. In a
mixture of N2 and B27 media, cells formed well-connected
networks expressing NeuN and NF (Figure 2B). These cells
also expressed β-III tubulin and microtubule-associated
protein 2 (MAP2) (data not shown). The neuronal markers
were evident as early as 7 days after re-plating for terminal
differentiation (Figure 2B-a) and persisted through 4 weeks
of culture (Figure 2B-b,c). In addition to these general
markers, cells with a neuronal morphology expressed the 2-
amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid
(AMPA) receptor subunit GluA1 and the N-methyl-
D-aspartic acid (NMDA) receptor subunit GluN2B
(Figure 2C). Western blotting also revealed the presence
of the NMDA receptor subunits GluN1 and GluN3A
(Figure 2C-c), the AMPA receptor subunit GluA2, and the
sodium channel subunit (Nav1.1) (data not shown). Nestinrentiate into mature neurons in vitro. (A) Neural precursors at day
stin (n = 4), 75% ± 7% expressed PAX6 (n = 4), and 64% ± 9%
nal differentiation, cells positive for NeuN (red) and NF (green) were
ed large networks across the culture, and co-localization of NeuN and
e AMPA and NMDA receptors GluA1, GluN1, GluN2B, and GluN3A.
Nestin was still present in these cultures through 21 days. Scale bars
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21, suggesting that some of the underlying cells were still
precursors. However, this expression was lost by day 28
(Figure 2C-c). GFAP was also detected by Western blot-
ting at 14, 21, and 28 days of terminal differentiation,
suggesting astrocytic differentiation (not shown).
Human embryonic stem cell-derived neuronal cells
display functional electrophysiological properties in vitro
To measure electrophysiological function in hES cell-de-
rived neuronal cells, we performed whole-cell patch-clamp
recording over the course of 4 weeks of differentiation.
Action potentials displayed a pattern of maturation
over the 4-week differentiation period (Figure 3). At 1
week, the evoked response was slow and weak, and the
mean amplitude was 33.2 ± 3.2 mV. After 2 weeks of
terminal differentiation, most cells fired significantly
stronger action potentials with single sharp spikes at a
mean amplitude of 69.1 ± 1.7 mV. Further maturation
increased this response to a mean amplitude of 78.0 ±
2.0 mV at 3 weeks, and there was no further significant
change at 4 weeks. Three weeks of terminal differenti-
ation was also the point at which repetitive trains of ac-
tion potentials were first observed, and approximately 1
out of 7 of cells exhibited multiple action potentials in
response to a single depolarization event. Although no
significant change in amplitude was observed from 3 to
4 weeks of differentiation, the proportion of cells firing
repetitive trains increased to approximately 1 out of 3 ofFigure 3 hES cell-derived neurons exhibit mature action potential res
to depolarization at 1, 2, 3, and 4 weeks after re-plating for terminal differe
trains of action potentials at 3 and 4 weeks, respectively. (B) Quantification
SEM. A significant increase was observed from 1 to 2 weeks and again from
***P <0.001.the cells examined. Miniature excitatory post-synaptic
potentials were evident in cultures at all measured time
points (data not shown), indicating functional synapse
formation between cells.
We also examined changes in potassium currents in
differentiating cells (Figure 4). The delayed outward rec-
tifier current density declined over time with neuronal
differentiation, from 206.6 ± 36.4 pA/pF at 1 week to
111.2 ± 13.2 pA/pF at 2 weeks. This decreasing trend
continued over time, but no further statistically signifi-
cant change was observed between weeks 3 and 4 of ter-
minal differentiation. The fast transient outward current
density, on the other hand, increased over time. Very
small current densities of 3.6 ± 0.5 pA/pF were observed
at 1 week, increasing to 35.4 ± 4.3 pA/pF at 2 weeks and
80.2 ± 6.0 pA/pF at 3 weeks into terminal differentiation.
Again, no further change was noted at 4 weeks of differ-
entiation. It is likely that the increased role of the transi-
ent outward K+ current contributed to the maturation of
the action potential response by allowing cells to repo-
larize more quickly.
Human embryonic stem cell-derived neural precursors
survive and differentiate into neurons in vivo
hES cell-derived neural progenitors were transplanted
into the ischemic core and penumbra regions 7 days
after ischemic stroke. Two to three days after transplant-
ation, one animal per group (n = 4) was sacrificed to
check for cell survival. Transplanted cells were identifiedponses. (A) Representative traces of action potentials fired in response
ntiation. Approximately 1 out of 7 and 1 out of 3 cells fired repetitive
of the maximum action potential amplitude presented as mean ±
2 to 3 weeks. n = 19 (1w), 23 (2w), 26 (3w), and 47 (4w). *P <0.05,
Figure 4 Potassium currents in hES cell-derived neurons mature over 4 weeks in culture. (A) Representative traces of the delayed rectifier
K+ current in hES cell-derived neurons. (B) Quantification of the peak delayed rectifier current density at +40 mV. The current densities measured
in the first week of terminal differentiation were significantly higher than all later measurements. (C) Representative traces of the transient
outward K+ current in hES cell-derived neurons. (D) Quantification of the peak transient outward current density at +40 mV. Current densities
significantly increased from week 1 to week 2 and then again at week 3. n = 7 (1w), 9 (2w), 11 (3w), 12 (4w). **P <0.01, ***P <0.001, ##P <0.01 as
compared with 1 week, ###P <0.001 as compared with 1 week.
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to assess cell death. Although there was some TUNEL
staining present in the graft area, co-localization with
Hoechst-positive cells was negligible (Figure 5A). Cell sur-
vival was further indicated by the fact that the Hoechst tag
was still visible in a large number of cells in the stroke core
and penumbra of transplant animals after 28 days in vivo
(Figure 5B-b). Hoechst 33342-positive cells in the grafted
core/peri-infarct region were 5,541 ± 180 (averaged total
number from six sections per animals; n = 3 mice). Neur-
onal differentiation of transplanted cells was assessed by
quantifying Hoechst 33342 co-localization with NeuN in
the penumbra region (Figure 5B-c). At day 28, the per-
centage of Hoechst-positive cells that were also NeuN-
positive was highly variable between animals, ranging from
13.5% to 40.8%, and the mean value was 20.6% ± 10.3%.
Hoechst 33342 co-localization with MAP2 was also ob-
served (data not shown), further indicating neuronal dif-
ferentiation. Some Hoechst-positive cells (14.6% ± 2.4%)
did co-localize with vessels, but whether the cells
were part of the vessels or migrating along them was
not clear.Transplantation increases the proportion of
bromodeoxyuridine-positive neurons at 28 days
Animals received daily injections of BrdU beginning on
the day of the transplant in order to track the fate of new-
born cells. No difference in the total number of BrdU-
positive cells in the penumbra was observed between
animals receiving cell transplantation and medium con-
trols. However, the percentage of BrdU-positive cells co-
localized with NeuN was 9.6% ± 0.5% in the transplant
group (n = 8), which is significantly higher than the 5.2% ±
0.7% observed in the control group (n = 6) (Figure 6). This
indicates an increase in the number of newborn neurons in
the transplant group, although BrdU may also be incorpo-
rated into cells undergoing DNA repair. The fact that the
total density of BrdU-positive cells was not increased in
the transplant group suggests that proliferation in the graft
was low. This supports the hypothesis that BrdU incorpor-
ation represents endogenous regenerative activity but does
not fully exclude the contribution of proliferation or repair
in graft-derived cells.
The number of BrdU-positive cells co-localized with
Col IV was examined as a marker of angiogenesis. In
Figure 6 Transplantation of hES cell-derived neural precursors increases BrdU co-localization with NeuN. (A) Representative images of
staining for NeuN (green), BrdU (red), and Col IV (blue) in the penumbra region of a medium control and a cell transplant animal. White arrows
indicate co-localization of NeuN and BrdU. Scale bars = 40 μm. (B) A significantly higher percentage of BrdU-positive cells in the transplant
animals co-localized with NeuN as compared with control animals, potentially indicating a higher degree of neurogenesis. ***P <0.001, n = 6
(control) and 8 (transplant). (C) No significant difference was observed in the percentage of BrdU-positive cells co-localized with Col IV, indicating
no difference in angiogenesis. n = 6 (control) and 7 (transplant).
Figure 5 hES cell-derived neural precursors survive and differentiate into neurons in vivo. (A) Representative example of graft survival 2
days after transplantation. The circle in (a) marks the graft area as determined by the Hoechst-tagged precursor cells. Arrows in (c) demonstrate
occasional TUNEL co-localization with Hoechst-positive cells. (B) Representative images stained for NeuN (red) and collagen IV (green) 28 days
after transplantation. No Hoechst-positive cells (blue) are evident in the medium control animal (a), whereas many transplanted cells are still
present in the transplant animal (b). The high-power image in (c) demonstrates co-localization of Hoechst 33342 and NeuN in the penumbra
region, indicating neuronal differentiation of transplanted cells. All scale bars = 10 μm.
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1.9% of BrdU-positive cells co-localized with Col IV in
the control group (n = 6) and 12.4% ± 1.1% in the trans-
plant group (n = 7) (P >0.05; Figure 6).
Transplantation improves functional recovery after stroke
Functional recovery was assessed by using the adhesive
removal test. On the affected side, both the time to con-
tact and the time to remove were significantly longer
after stroke (Table 1). As expected, neither of these mea-
sures was significantly different in either group on the
unaffected side. The post-stroke baseline measurements
were not significantly different between the control and
transplant groups (Table 2). The model-based estimate
of the mean outcome measures at each time point was
analyzed (Table 3). It is important to note that these are
not absolute measurements but instead are estimates
that incorporate the post-stroke impairment and the
learning curve observed on the unaffected side. There
was no significant difference between the outcome mea-
sures between the control and transplant groups at any
of the four time points. However, the estimated slope
over time in the mixed linear model of the longitudinal
outcome measures reveals a significant decreasing trend in
time to contact in the transplant group (estimated slope is
−0.15, P value = 0.012). This trend is not observed in the
control group (estimated slope is 0.06, P value = 0.314).
The time to remove does not change significantly across
time in either group. This suggests an improvement in the
sensory function of the forepaw in transplant animals as
compared with controls. Additionally, the variance of the
control group was significantly higher than that of the
transplant group in both measures, indicating a more con-
sistent recovery in treated animals.
Discussion
This study details the use of a fully adherent and feeder-
free differentiation protocol employing small molecules to
obtain neural precursors for transplantation after stroke.
Although there is still some batch-to-batch variation and
some animal products are still used, this protocol reduces
the heterogeneity present in suspension culture and re-
duces possible contamination from animal products by re-
moving the use of feeder cells in cell culture. Here, weTable 1 Performance in the adhesive removal task is
significantly altered by stroke
Measurements Control group Transplant group
(n = 17) (n = 18)
Affected side Time to contact P = 0.001 P = 0.001
Time to remove P <0.0001 P = 0.0004
Unaffected side Time to contact P = 0.627 P = 0.255
Time to remove P = 0.220 P = 0.091demonstrate that neural precursors derived by using this
protocol can develop into electrophysiologically active
neurons, suggesting that they have the potential to act
as functional neurons in damaged tissue. We further
demonstrate that neural precursors survive, differentiate
into neurons, improve neural regeneration, and enhance
sensory function after transplantation into the penumbra
region of stroke.
As we demonstrated during terminal differentiation, it
is possible for cells to express neuronal markers like
NeuN and neurofilament without exhibiting mature
electrophysiological function. It is important to ensure
that cells intended to replace lost tissue in the brain can
further differentiate into neurons and that those neurons
can respond appropriately to electrical signals. However,
many studies rely on protein expression, without testing
for electrophysiological function. Johnson et al. [28]
studied functional development in hES cell-derived (H9)
neurons over the course of 7 weeks of terminal differen-
tiation (10 weeks from the onset of differentiation in
hES cells). PAX6+/SOX1+ progenitors were obtained
within 2 weeks by using suspension culture and neural
rosette isolation, similar to our time course. These were
again cultured in suspension for 1 week before plating
for terminal differentiation in a medium containing
brain-derived neurotrophic factor and glial cell line-
derived neurotrophic factor, among other factors. Elec-
trophysiological properties were examined at 1, 3, 4, and
7 weeks after plating for terminal differentiation. High-
amplitude, single-spike action potentials were first
reported at 4 weeks of terminal differentiation, and re-
petitive trains were observed in some cells at 7 weeks. In
contrast, we obtained high-amplitude, single-spike ac-
tion potentials at only 2 weeks after plating for terminal
differentiation, and bFGF was the only growth factor
added to our base medium. We began to obtain repeti-
tive trains at 3 weeks of terminal differentiation, and the
proportion of cells firing them increased with another
week of culture. We have therefore greatly reduced the
time and cost associated with obtaining electrophysio-
logically active neurons in vitro. After transplantation,
cells differentiated into neuronal cells. Although the
present study could not verify the electrophysiological
properties of these cells, behavioral tests support the hy-
pothesis that the transplanted cells participated in func-
tional repair of damaged brain structures.
In this study, we examined neuronal differentiation
in vitro to confirm the ability of our hES cell-derived
neural precursors to further differentiate into neurons.
While these neurons were expressing receptor subunits
and electrical activity consistent with an excitatory
phenotype, we did not determine the exact subtype of
neurons we derived in vitro. This determination, along
with how environments approximating the stroke and
Table 2 No difference was found between groups in post-stroke performance
Measurements Control group Transplant group P value
(n = 17) (n = 18)
Affected side Time to contact 10.78 ± 15.17 9.26 ± 10.33 0.644
Time to remove 11.24 ± 8.02 20.25 ± 32.48 0.381
Unaffected side Time to contact 3.16 ± 3.90 2.65 ± 2.96 0.842
Time to remove 5.97 ± 2.40 7.33 ± 4.13 0.363
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portant as therapies move toward the clinic. To this
same end, it will be important to further identify the
non-neuronal cells in culture with an emphasis on
demonstrating that the cell types derived become post-
mitotic upon differentiation and do not form any in-
appropriate cell types. In this study, we used bFGF as
our only recombinant growth factor, but it is possible
that further patterning factors will increase the propor-
tion of neurons in culture and permit the derivation of
specific subtypes. Patterning factors are usually recom-
binant growth factors that can greatly increase the cost
of culture, but small molecules may lead to decreased
cost in this arena as well. For example, purmorphamine
is a sonic hedgehog (shh) agonist that has been used in
the derivation of dopaminergic neurons [53].
In vivo, we observed a very high degree of cell survival
after transplantation. This may have been due, in part,
to the presence of Matrigel throughout the differenti-
ation process. It was recently reported that hES cell-
derived neural precursors cultured with Matrigel before
transplantation or injected with a Matrigel scaffold re-
duced infarct size, improved behavioral outcomes, and
differentiated primarily into neuronal cells [22]. How-
ever, cells that were not exposed to Matrigel exhibited
high levels of cell death and lower proportions of neur-
onal markers and did not improve infarct size or behav-
ioral outcomes. We have also reported positive effects of
Matrigel on hES cell-derived neural precursors in vitro,
where we found that cells terminally differentiated on
poly-D-lysine/laminin-coated dishes never developed
mature action potential responses but that those grown
on Matrigel-coated dishes did [40]. Thus, the use ofTable 3 Time to contact improves over time in animals receiv
Measurements Estimated me
7 days 14 days
Time to contact Transplant 7.19 (1.20) 5.06 (1.19)
Control 5.87 (1.26) 4.21 (1.22)
P value 0.442 0.617
Time to remove Transplant 10.74 (0.95) 9.30 (0.95)
Control 9.95 (0.97) 7.99 (0.96)
P value 0.567 0.351
SE standard error.Matrigel throughout our differentiation process may
have contributed to the positive results we report here.
However, Matrigel will need to be removed from the
process if it is ever used in human trials, as the removal
of xenogenic products is largely seen as necessary for
widespread clinical use [54].
One major concern with the use of pluripotent stem
cells in cell therapy is the fear of tumor formation. We
did not observe any teratoma formation and this was
likely due the lack of residual pluripotent cells in our
cultures. However, pluripotent cells need not be present
for tumor formation. For example, small rosette-like tu-
mors can form if hES cell-derived neural precursors are
transplanted at a stage of differentiation in which cells
are highly proliferative but not yet similar to fetal brain
in the expression of neural markers [24]. These cells
expressed high levels of PAX6 but had only low-level ex-
pression of SOX1, whereas the neural precursor stage,
which did not result in any tumor formation, expressed
high levels of both markers. The cells we obtain with
small-molecule SMAD inhibition also highly expressed
both of these markers, and we observed no adverse ef-
fects from cell proliferation in the brain tissue. In fact,
the total numbers of BrdU-positive cells found in the
control and transplant groups were not significantly dif-
ferent, suggesting low levels of proliferation in the graft.
Another concern in our model may have been the use of
the Hoechst tag for tracking, as it has the potential to cause
problems in DNA replication or leak into neighboring
cells. However, this tag has been successfully used in prior
studies [17], and we did not observe any tumor formation
in vivo. As argued earlier, it is likely that the transplanted
cells were not proliferative, mitigating any problems withing transplant
an (SE) Slope across time
21 days 28 days Estimated slope (SE) P value
4.65 (1.19) 3.75 (1.18) −0.15 (0.06) 0.012
4.79 (1.22) 4.11 (1.22) −0.06 (0.06) 0.314
0.936 0.833
9.55 (0.95) 10.10 (0.95) −0.02 (0.05) 0.652
9.55 (0.97) 10.21 (0.99) 0.04 (0.05) 0.497
0.998 0.936
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method may be something akin to that used by Daadi
et al. [25]. Transfection of cells with an easily identifiable
marker that does not leak and can be easily co-stained
would be ideal. The additional inclusion of a biolumines-
cent marker or superparamagnetic iron oxide (SPIO) tag
would also allow for in vivo monitoring in live animals.
A different tracking method would also help to better
differentiate between endogenous and graft-derived neuro-
genesis. In previous studies with this stroke model, we
have shown that newborn cells that express doublecortin
(DCX) and incorporate BrdU migrate from the SVZ to the
stroke region and form new neurons. Other interventions,
such as whisker stimulation, can increase the number of
neuroblasts migrating toward the stroke region at early
time points and new neurons in the penumbra region 4
weeks after stroke [55]. This response could be enhanced
by the transplantation of neural precursors, but this hy-
pothesis remains to be verified by using more specific
markers and technologies.
BrdU incorporation is the most commonly used and
clearest measure for tracking the fate of newborn cells in
the nervous system [56,57], as it remains in the cell even
after it differentiates and leaves the cell cycle, but there
are concerns with its use. Because BrdU incorporates
during DNA replication, it is possible that labeled cells
may have been undergoing cell repair (successfully or
prior to apoptosis) rather than mitosis [58]. In unpub-
lished studies, we have found little to no co-staining of
TUNEL and BrdU in this model, and none of the
counted cells showed morphological signs of apoptosis
or necrosis, so it is unlikely that the BrdU-positive cells
we observed were dying. It is also unlikely that our dose
of 50 mg/kg would be sufficient to visualize cells under-
going repair [59], although an increase in successful cell
repair would also be a desirable outcome of transplant-
ation. Future studies will need to differentiate between
cell repair and true neurogenesis by examining earlier
time points and quantifying DCX-positive neuroblasts
migrating to the stroke region after treatment.
Our previous unpublished studies have demonstrated
no change in graft survival in this model when immune
suppression is administered and we chose not to use it
in this study. However, it is possible that we would have
been able to achieve greater or more consistent levels of
neuronal differentiation in vivo if immune suppression
had been used. In a transplant model using mouse em-
bryonic stem-cell derived neurospheres, graft survival
was unchanged by the administration of cyclosporine A,
but inflammatory factors biased cells toward glial differ-
entiation rather than neuronal differentiation when it
was not given [60]. This may have occurred in our
model as well, although we likely mitigated this effect by
transplanting 7 days after stroke, when inflammation inthe stroke region has largely subsided. It is also import-
ant to note that immune suppression may be detrimen-
tal to healing after stroke. Inflammatory signals can
attract stem cells to the site of injury [61], and the im-
mune response may be neuroprotective and necessary
for endogenous neurogenesis [62-65]. Additionally, the
immune system is already naturally suppressed after
stroke [66], and further suppression may increase the
risks of infection and tumor formation [67,68]. It is thus
clear that systemic immune suppression in patients with
stroke should be avoided wherever possible.
Conclusions
We have demonstrated that neural precursors derived
from hES cells by using small-molecule SMAD inhib-
ition in a fully adherent protocol can differentiate into
neurons both in vitro and in vivo after transplantation
into the ischemic brain. This protocol reduces the het-
erogeneity, cost, and use of animal products in obtaining
hES cell-derived neural precursors that can differentiate
into electrophysiologically active neurons and allows for
transplantation at a safe stage of differentiation. Trans-
plantation of these cells improves regenerative activities
and sensory function even without immune suppression.
Further studies will be needed to fully characterize the
integration of these cells into the damaged tissue and
the paracrine effects on endogenous healing.
Abbreviations
AMPA: 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid;
AP: Alkaline phosphatase; bFGF: Basic fibroblast growth factor;
BrdU: Bromodeoxyuridine; CCA: Common carotid arteries; Col IV: Collagen IV;
DCX: Doublecortin; GFAP: Glial fibrillary acidic protein; hES: Human
embryonic stem; HRP: Horseradish peroxidase; MAP2: Microtubule-associated
protein 2; NeuN: Neuronal nuclei; NF: Neurofilament L; NMDA: N-methyl-D-
aspartic acid; PAX6: Paired box gene 6; SEM: Standard error of the mean;
SOX1: Sex-determining region Y-box 1; SVZ: Subventricular zone;
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DD-S carried out the cell and tissue processing, staining, Western blots, and
most statistical analyses; participated in the study design; and drafted the
manuscript. MS carried out the electrophysiological measurements. OM
aided in cell culture, study design, and manuscript revision. YG designed and
carried out the statistical analysis of the adhesive removal tests and
contributed to the drafting of the manuscript. XG carried out all animal
surgeries. DC aided in immunohistochemistry and cell quantification. LW
helped in initiation of the research idea, participated in the study design,
and revised the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
This work was supported by National Institutes of Health (NIH) grants
NS0458710, NS 057255, NS075338, and NS062097. This work was also
supported by the NIH grant C06 RR015455 from the Extramural Research
Facilities Program of the National Center for Research Resources. Some of
the data presented here were included in a dissertation by DD-S that will be
published by Proquest/UMI Dissertation Publishing. The authors are grateful
for helpful discussion with Shan Ping Yu and his support during this
investigation.
Drury-Stewart et al. Stem Cell Research & Therapy 2013, 4:93 Page 12 of 13
http://stemcellres.com/content/4/4/93Author details
1Department of Anesthesiology, Emory University, 101 Woodruff Circle,
Atlanta, GA 30322, USA. 2Department of Biomedical Engineering, Georgia
Institute of Technology, 15 Ferst Drive, NW, Atlanta, GA 30332, USA.
3Department of Biostatistics and Bioinformatics, Emory University, 1518
Clifton Road, NE, Atlanta, GA 30322, USA.
Received: 11 January 2013 Revised: 25 January 2013
Accepted: 26 July 2013 Published: 8 August 2013
References
1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB,
Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM,
Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,
Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS,
Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD,
Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American
Heart Association Statistics Committee and Stroke Statistics Subcommittee:
Executive summary: heart disease and stroke statistics-2012 update: a
report from the American Heart Association. Circulation 2012,
125:188–197.
2. Durukan A, Tatlisumak T: Acute ischemic stroke: overview of major
experimental rodent models, pathophysiology, and therapy of focal
cerebral ischemia. Pharmacol Biochem Behav 2007, 87:179–197.
3. Hrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg
K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M,
Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H,
Schwendemann G, Dengler R, Kastrup A, Bartels C, EPO Stroke Trial Group:
Recombinant human erythropoietin in the treatment of acute ischemic
stroke. Stroke 2009, 40:e647–e656.
4. Wei L, Keogh CL, Whitaker VR, Theus MH, Yu SP: Angiogenesis and stem
cell transplantation as potential treatments of cerebral ischemic stroke.
Pathophysiology 2005, 12:47–62.
5. Yu D, Silva GA: Stem cell sources and therapeutic approaches for central
nervous system and neural retinal disorders. Neurosurg Focus 2008,
24:E11.
6. Hess DC, Borlongan CV: Cell-based therapy in ischemic stroke. Expert Rev
Neurother 2008, 8:1193–1201.
7. Pollock K, Stroemer P, Patel S, Stevanato L, Hope A, Miljan E, Dong Z,
Hodges H, Price J, Sinden JD: A conditionally immortal clonal stem cell
line from human cortical neuroepithelium for the treatment of ischemic
stroke. Exp Neurol 2006, 199:143–155.
8. Stevanato L, Corteling RL, Stroemer P, Hope A, Heward J, Miljan EA, Sinden
JD: c-MycERTAM transgene silencing in a genetically modified human
neural stem cell line implanted into MCAo rodent brain. BMC Neurosci
2009, 10:86.
9. Mack GS: ReNeuron and StemCells get green light for neural stem cell
trials. Nat Biotechnol 2011, 29:95–97.
10. Jin K, Xie L, Mao X, Greenberg MB, Moore A, Peng B, Greenberg RB,
Greenberg DA: Effect of human neural precursor cell transplantation on
endogenous neurogenesis after focal cerebral ischemia in the rat.
Brain Res 2011, 1374:56–62.
11. Bliss TM, Kelly S, Shah AK, Foo WC, Kohli P, Stokes C, Sun GH, Ma M, Masel J,
Kleppner SR, Schallert T, Palmer T, Steinberg GK: Transplantation of hNT
neurons into the ischemic cortex: cell survival and effect on
sensorimotor behavior. J Neurosci Res 2006, 83:1004–1014.
12. Hara K, Yasuhara T, Maki M, Matsukawa N, Masuda T, Yu SJ, Ali M, Yu G, Xu
L, Kim SU, Hess DC, Borlongan CV: Neural progenitor NT2N cell lines from
teratocarcinoma for transplantation therapy in stroke. Prog Neurobiol
2008, 85:318–334.
13. Zhang P, Li J, Liu Y, Chen X, Kang Q: Transplanted human embryonic
neural stem cells survive, migrate, differentiate and increase
endogenous nestin expression in adult rat cortical peri-infarction zone.
Neuropathology 2009, 29:410–421.
14. Andres RH, Horie N, Slikker W, Keren-Gill H, Zhan K, Sun G, Manley NC,
Pereira MP, Sheikh LA, McMillan EL, Schaar BT, Svendsen CN, Bliss TM,
Steinberg GK: Human neural stem cells enhance structural plasticity and
axonal transport in the ischaemic brain. Brain 2011, 134:1777–1789.
15. Nakagomi N, Nakagomi T, Kubo S, Nakano-Doi A, Saino O, Takata M,
Yoshikawa H, Stern DM, Matsuyama T, Taguchi A: Endothelial cells support
survival, proliferation, and neuronal differentiation of transplanted adultischemia-induced neural stem/progenitor cells after cerebral infarction.
Stem Cells 2009, 27:2185–2195.
16. Prajerova I, Honsa P, Chvatal A, Anderova M: Neural stem/progenitor cells
derived from the embryonic dorsal telencephalon of D6/GFP mice
differentiate primarily into neurons after transplantation into a cortical
lesion. Cell Mol Neurobiol 2010, 30:199–218.
17. Wei L, Cui L, Snider BJ, Rivkin M, Yu SS, Lee CS, Adams LD, Gottlieb DI,
Johnson EM Jr, Yu SP, Choi DW: Transplantation of embryonic stem cells
overexpressing Bcl-2 promotes functional recovery after transient
cerebral ischemia. Neurobiol Dis 2005, 19:183–193.
18. Yanagisawa D, Qi M, Kim DH, Kitamura Y, Inden M, Tsuchiya D, Takata K,
Taniguchi T, Yoshimoto K, Shimohama S, Akaike A, Sumi S, Inoue K:
Improvement of focal ischemia-induced rat dopaminergic dysfunction
by striatal transplantation of mouse embryonic stem cells. Neurosci Lett
2006, 407:74–79.
19. Theus MH, Wei L, Cui L, Francis K, Hu X, Keogh C, Yu SP: In vitro hypoxic
preconditioning of embryonic stem cells as a strategy of promoting cell
survival and functional benefits after transplantation into the ischemic
rat brain. Exp Neurol 2008, 210:656–670.
20. Daadi MM, Maag AL, Steinberg GK: Adherent self-renewable human
embryonic stem cell-derived neural stem cell line: functional
engraftment in experimental stroke model. PLoS One 2008, 3:e1644.
21. Kim DY, Park SH, Lee SU, Choi DH, Park HW, Paek SH, Shin HY, Kim EY, Park
SP, Lim JH: Effect of human embryonic stem cell-derived neuronal
precursor cell transplantation into the cerebral infarct model of rat with
exercise. Neurosci Res 2007, 58:164–175.
22. Jin K, Mao X, Xie L, Galvan V, Lai B, Wang Y, Gorostiza O, Wang X,
Greenberg DA: Transplantation of human neural precursor cells in
Matrigel scaffolding improves outcome from focal cerebral ischemia
after delayed postischemic treatment in rats. J Cereb Blood Flow Metab
2010, 30:534–544.
23. Jin K, Mao X, Xie L, Greenberg RB, Peng B, Moore A, Greenberg MB,
Greenberg DA: Delayed transplantation of human neural precursor cells
improves outcome from focal cerebral ischemia in aged rats. Aging Cell
2010, 9:1076–1083.
24. Seminatore C, Polentes J, Ellman D, Kozubenko N, Itier V, Tine S, Tritschler L,
Brenot M, Guidou E, Blondeau J, Lhuillier M, Bugi A, Aubry L, Jendelova P,
Sykova E, Perrier AL, Finsen B, Onteniente B: The postischemic
environment differentially impacts teratoma or tumor formation after
transplantation of human embryonic stem cell-derived neural
progenitors. Stroke 2010, 41:153–159.
25. Daadi MM, Li Z, Arac A, Grueter BA, Sofilos M, Malenka RC, Wu JC, Steinberg
GK: Molecular and magnetic resonance imaging of human embryonic
stem cell-derived neural stem cell grafts in ischemic rat brain.
Mol Ther 2009, 17:1282–1291.
26. Darsalia V, Allison SJ, Cusulin C, Monni E, Kuzdas D, Kallur T, Lindvall O,
Kokaia Z: Cell number and timing of transplantation determine survival
of human neural stem cell grafts in stroke-damaged rat brain.
J Cereb Blood Flow Metab 2011, 31:235–242.
27. Smukler SR, Runciman SB, Xu S, van der Kooy D: Embryonic stem cells
assume a primitive neural stem cell fate in the absence of extrinsic
influences. J Cell Biol 2006, 172:79–90.
28. Johnson MA, Weick JP, Pearce RA, Zhang SC: Functional neural
development from human embryonic stem cells: accelerated synaptic
activity via astrocyte coculture. J Neuroimmune Pharmacol 2007,
27:3069–3077.
29. Cohen MA, Itsykson P, Reubinoff BE: Neural differentiation of human ES
cells. Curr Protoc Cell Biol 2007, Chapter 23:Unit 23.7.
30. Kim DS, Lee JS, Leem JW, Huh YJ, Kim JY, Kim HS, Park IH, Daley GQ, Hwang
DY, Kim DW: Robust enhancement of neural differentiation from human
ES and iPS cells regardless of their innate difference in differentiation
propensity. Stem Cell Rev 2010, 6:270–281.
31. Morizane A, Doi D, Kikuchi T, Nishimura K, Takahashi J: Small-molecule
inhibitors of bone morphogenic protein and activin/nodal signals
promote highly efficient neural induction from human pluripotent stem
cells. J Neurosci Res 2011, 89:117–126.
32. Tavakoli T, Xu X, Derby E, Serebryakova Y, Reid Y, Rao MS, Mattson MP, Ma W:
Self-renewal and differentiation capabilities are variable between human
embryonic stem cell lines I3, I6 and BG01V. BMC Cell Biol 2009, 10:44.
33. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X: Efficient
generation of functional dopaminergic neurons from human induced
Drury-Stewart et al. Stem Cell Research & Therapy 2013, 4:93 Page 13 of 13
http://stemcellres.com/content/4/4/93pluripotent stem cells under defined conditions. Stem Cells 2010,
28:1893–1904.
34. Vazin T, Chen J, Lee CT, Amable R, Freed WJ: Assessment of stromal-
derived inducing activity in the generation of dopaminergic neurons
from human embryonic stem cells. Stem Cells 2008, 26:1517–1525.
35. Lee H, Shamy GA, Elkabetz Y, Schofield CM, Harrsion NL, Panagiotakos G,
Socci ND, Tabar V, Studer L: Directed differentiation and transplantation
of human embryonic stem cell-derived motoneurons. Stem Cells 2007,
25:1931–1939.
36. Itsykson P, Ilouz N, Turetsky T, Goldstein RS, Pera MF, Fishbein I, Segal M,
Reubinoff BE: Derivation of neural precursors from human embryonic
stem cells in the presence of noggin. Mol Cell Neurosci 2005, 30:24–36.
37. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer
L: Highly efficient neural conversion of human ES and iPS cells by dual
inhibition of SMAD signaling. Nat Biotechnol 2009, 27:275–280.
38. Gerrard L, Rodgers L, Cui W: Differentiation of human embryonic stem
cells to neural lineages in adherent culture by blocking bone
morphogenetic protein signaling. Stem Cells 2005, 23:1234–1241.
39. Zhou J, Su P, Li D, Tsang S, Duan E, Wang F: High-efficiency induction of
neural conversion in human ESCs and human induced pluripotent stem
cells with a single chemical inhibitor of transforming growth factor beta
superfamily receptors. Stem Cells 2010, 28:1741–1750.
40. Drury-Stewart DSM, Mohamad O, Yu SP, Wei L: Small molecule promoted
adherent and feeder free differentiation of functional neurons from
human embryonic and induced pluripotent stem cells. J Stem Cells 2012,
6:1–8.
41. Whitaker VR, Cui L, Miller S, Yu SP, Wei L: Whisker stimulation enhances
angiogenesis in the barrel cortex following focal ischemia in mice.
J Cereb Blood Flow Metab 2007, 27:57–68.
42. Francis KR, Wei L: Human embryonic stem cell neural differentiation and
enhanced cell survival promoted by hypoxic preconditioning.
Cell Death Disease 2010, 1:e22.
43. Wei L, Rovainen CM, Woolsey TA: Ministrokes in rat barrel cortex.
Stroke 1995, 26:1459–1462.
44. Wei L, Craven K, Erinjeri J, Liang GE, Bereczki D, Rovainen CM, Woolsey TA,
Fenstermacher JD: Local cerebral blood flow during the first hour
following acute ligation of multiple arterioles in rat whisker barrel
cortex. Neurobiol Dis 1998, 5:142–150.
45. Wei L, Erinjeri JP, Rovainen CM, Woolsey TA: Collateral growth and
angiogenesis around cortical stroke. Stroke 2001, 32:2179–2184.
46. Bouet V, Boulouard M, Toutain J, Divoux D, Bernaudin M, Schumann-Bard P,
Freret T: The adhesive removal test: a sensitive method to assess
sensorimotor deficits in mice. Nat Protoc 2009, 4:1560–1564.
47. Michalczyk K, Ziman M: Nestin structure and predicted function in cellular
cytoskeletal organisation. Histol Histopathol 2005, 20:665–671.
48. Walker AS, Goings GE, Kim Y, Miller RJ, Chenn A, Szele FG: Nestin reporter
transgene labels multiple central nervous system precursor cells.
Neural Plast 2010, 2010:894374.
49. Georgala PA, Carr CB, Price DJ: The role of Pax6 in forebrain development.
Dev Neurobiol 2011, 71:690–709.
50. Georgala PA, Manuel M, Price DJ: The generation of superficial cortical
layers is regulated by levels of the transcription factor Pax6. Cereb Cortex
2011, 21:81–94.
51. Simpson TI, Pratt T, Mason JO, Price DJ: Normal ventral telencephalic
expression of Pax6 is required for normal development of
thalamocortical axons in embryonic mice. Neural Dev 2009, 4:19.
52. Pevny LH, Sockanathan S, Placzek M, Lovell-Badge R: A role for SOX1 in
neural determination. Development 1998, 125:1967–1978.
53. Stacpoole SR, Bilican B, Webber DJ, Luzhynskaya A, He XL, Compston A,
Karadottir R, Franklin RJ, Chandran S: Efficient derivation of NPCs, spinal
motor neurons and midbrain dopaminergic neurons from hESCs at 3%
oxygen. Nat Protoc 2011, 6:1229–1240.
54. Lin G, Xu RH: Progresses and challenges in optimization of human
pluripotent stem cell culture. Curr Stem Cell Res Ther 2010, 5:207–214.
55. Li WL, Yu SP, Ogle ME, Ding XS, Wei L: Enhanced neurogenesis and cell
migration following focal ischemia and peripheral stimulation in mice.
Dev Neurobiol 2008, 68:1474–1486.
56. Kee N, Sivalingam S, Boonstra R, Wojtowicz JM: The utility of Ki-67 and
BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods
2002, 115:97–105.57. Landgren H, Curtis MA: Locating and labeling neural stem cells in the
brain. J Cell Physiol 2011, 226:1–7.
58. Rakic P: Adult neurogenesis in mammals: an identity crisis. J Neurosci
2002, 22:614–618.
59. Cooper-Kuhn CM, Kuhn HG: Is it all DNA repair? Methodological
considerations for detecting neurogenesis in the adult brain. Brain Res
Dev Brain Res 2002, 134:13–21.
60. Ideguchi M, Shinoyama M, Gomi M, Hayashi H, Hashimoto N, Takahashi J:
Immune or inflammatory response by the host brain suppresses
neuronal differentiation of transplanted ES cell-derived neural precursor
cells. J Neurosci Res 2008, 86:1936–1943.
61. Ben-Hur T, Ben-Menachem O, Furer V, Einstein O, Mizrachi-Kol R, Grigoriadis
N: Effects of proinflammatory cytokines on the growth, fate, and motility
of multipotential neural precursor cells. Mol Cell Neurosci 2003,
24:623–631.
62. Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M: Synergy between
immune cells and adult neural stem/progenitor cells promotes
functional recovery from spinal cord injury. Proc Natl Acad Sci USA 2006,
103:13174–13179.
63. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, Cohen H, Kipnis J,
Schwartz M: Immune cells contribute to the maintenance of
neurogenesis and spatial learning abilities in adulthood. Nat Neurosci
2006, 9:268–275.
64. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH: CD4+ T cells support glial
neuroprotection, slow disease progression, and modify glial morphology
in an animal model of inherited ALS. Proc Natl Acad Sci USA 2008,
105:15558–15563.
65. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH Jr,
Carroll MC: T lymphocytes potentiate endogenous neuroprotective
inflammation in a mouse model of ALS. Proc Natl Acad Sci USA 2008,
105:17913–17918.
66. Vogelgesang A, Dressel A: Immunological consequences of ischemic
stroke: immunosuppression and autoimmunity. J Neuroimmunol 2011,
231:105–110.
67. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer
immunosurveillance and immunoediting. Immunity 2004, 21:137–148.
68. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting:
from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991–998.
doi:10.1186/scrt292
Cite this article as: Drury-Stewart et al.: Highly efficient differentiation of
neural precursors from human embryonic stem cells and benefits of
transplantation after ischemic stroke in mice. Stem Cell Research &
Therapy 2013 4:93.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
